$TCRT
Alaunos Therapeutics, Inc.

2012 Q2 Form 10-Q Financial Statement

#000114420412025871 Filed on May 03, 2012

View on sec.gov

Income Statement

Concept 2012 Q2 2012 Q1 2011 Q1
Revenue $200.0K $200.0K $67.00K
YoY Change 0.0% 198.51%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.900M $4.850M $3.350M
YoY Change 25.0% 44.78% 27.38%
% of Gross Profit
Research & Development $18.26M $13.99M $17.50M
YoY Change 100.04% -20.09% 802.06%
% of Gross Profit
Depreciation & Amortization $150.0K $120.0K $40.00K
YoY Change 150.0% 200.0% -42.86%
% of Gross Profit
Operating Expenses $18.26M $13.99M $17.50M
YoY Change 39.95% -20.09% 282.93%
Operating Profit -$22.97M -$18.63M -$27.93M
YoY Change 78.75% -33.28%
Interest Expense -$650.0K -$5.810M -$11.08M
YoY Change -130.66% -47.56% -15.36%
% of Operating Profit
Other Income/Expense, Net $3.000K -$26.00K -$2.000K
YoY Change -70.0% 1200.0% -120.0%
Pretax Income -$23.61M -$24.47M -$39.01M
YoY Change 120.24% -37.27% 121.02%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$23.61M -$24.47M -$39.01M
YoY Change 120.19% -37.27% 121.01%
Net Earnings / Revenue -11806.5% -12235.0% -58220.9%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.30 -$0.32 -$0.65
COMMON SHARES
Basic Shares Outstanding 79.52M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2012 Q2 2012 Q1 2011 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $110.4M $128.0M $124.0M
YoY Change -15.27% 3.23% 175.56%
Cash & Equivalents $110.4M $128.0M $124.0M
Short-Term Investments
Other Short-Term Assets $9.100M $10.80M $900.0K
YoY Change 810.0% 1100.0% 200.0%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $5.000M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $119.4M $138.8M $130.0M
YoY Change -9.06% 6.78% 186.34%
LONG-TERM ASSETS
Property, Plant & Equipment $2.000M $1.177M $400.0K
YoY Change 300.0% 194.25% 100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.000M $794.0K $400.0K
YoY Change 0.0% 98.5% 33.33%
Total Long-Term Assets $3.000M $2.062M $900.0K
YoY Change 100.0% 129.11% 125.0%
TOTAL ASSETS
Total Short-Term Assets $119.4M $138.8M $130.0M
Total Long-Term Assets $3.000M $2.062M $900.0K
Total Assets $122.4M $140.9M $130.9M
YoY Change -7.83% 7.62% 185.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.500M $1.984M $1.900M
YoY Change -16.67% 4.42% 26.67%
Accrued Expenses $15.50M $11.53M $3.900M
YoY Change 154.1% 195.74% 200.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.80M $14.33M $6.500M
YoY Change 104.6% 120.46% 132.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $29.00M $25.19M $42.40M
YoY Change -27.5% -40.58% 34.18%
Total Long-Term Liabilities $29.00M $25.19M $42.40M
YoY Change -27.5% -40.58% 34.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.80M $14.33M $6.500M
Total Long-Term Liabilities $29.00M $25.19M $42.40M
Total Liabilities $46.70M $43.17M $48.90M
YoY Change -4.11% -11.71% 41.74%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $302.7M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $75.60M $97.70M $82.00M
YoY Change
Total Liabilities & Shareholders Equity $122.4M $140.9M $130.9M
YoY Change -7.83% 7.62% 185.81%

Cashflow Statement

Concept 2012 Q2 2012 Q1 2011 Q1
OPERATING ACTIVITIES
Net Income -$23.61M -$24.47M -$39.01M
YoY Change 120.19% -37.27% 121.01%
Depreciation, Depletion And Amortization $150.0K $120.0K $40.00K
YoY Change 150.0% 200.0% -42.86%
Cash From Operating Activities -$16.77M -$25.86M -$8.167M
YoY Change 188.14% 216.64% 115.49%
INVESTING ACTIVITIES
Capital Expenditures $960.0K $154.0K $227.0K
YoY Change 500.0% -32.16% 2170.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities -$960.0K -$154.0K -$227.0K
YoY Change 500.0% -32.16% 2170.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $52.60M -$11.52M
YoY Change -556.52%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 100.0K 49.31M 72.04M
YoY Change -99.18% -31.55%
NET CHANGE
Cash From Operating Activities -16.77M -25.86M -8.167M
Cash From Investing Activities -960.0K -154.0K -227.0K
Cash From Financing Activities 100.0K 49.31M 72.04M
Net Change In Cash -17.63M 23.30M 63.65M
YoY Change -382.08% -63.4% -1774.87%
FREE CASH FLOW
Cash From Operating Activities -$16.77M -$25.86M -$8.167M
Capital Expenditures $960.0K $154.0K $227.0K
Free Cash Flow -$17.73M -$26.01M -$8.394M
YoY Change 196.49% 209.91% 120.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
79522502 shares
CY2011Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124037000
CY2012Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
794000
CY2012Q1 us-gaap Liabilities Current
LiabilitiesCurrent
14330000
CY2012Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
800000
CY2012Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
12000
CY2012Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11534000
CY2012Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10803000
CY2012Q1 us-gaap Assets
Assets
140873000
CY2012Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3333000
CY2012Q1 us-gaap Common Stock Value
CommonStockValue
80000
CY2012Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q1 us-gaap Other Additional Capital
OtherAdditionalCapital
7079000
CY2012Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
316000
CY2012Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79532882 shares
CY2012Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2012Q1 us-gaap Assets Current
AssetsCurrent
138811000
CY2012Q1 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
212062000
CY2012Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
25194000
CY2012Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
128008000
CY2012Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
302603000
CY2012Q1 us-gaap Stockholders Equity
StockholdersEquity
97700000
CY2012Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
79532882 shares
CY2012Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3533000
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
69000
CY2012Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
140873000
CY2012Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1177000
CY2012Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2012Q1 us-gaap Liabilities
Liabilities
43173000
CY2012Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
91000
CY2012Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1984000
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60392000
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
771000
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13363000
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
800000
CY2011Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
15000
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10821000
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1313000
CY2011Q4 us-gaap Assets
Assets
108108000
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Other Additional Capital
OtherAdditionalCapital
12611000
CY2011Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
180000
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69206044 shares
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2011Q4 us-gaap Assets Current
AssetsCurrent
106105000
CY2011Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
187592000
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
19425000
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2011Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
79000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104713000
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
108108000
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2011Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
246519000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
71607000
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69206044 shares
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1141000
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2011Q4 us-gaap Liabilities
Liabilities
36501000
CY2011Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
91000
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1727000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
794000
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
500000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2321000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1343000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3220000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4688000
us-gaap Income Taxes Paid
IncomeTaxesPaid
us-gaap Revenues
Revenues
867000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12889000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-168668000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
17457000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
394000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-1090000
us-gaap Share Based Compensation
ShareBasedCompensation
16513000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-9000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
11534000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
216527000
us-gaap Net Income Loss
NetIncomeLoss
-212062000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
142884000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3221000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2034000
us-gaap Operating Income Loss
OperatingIncomeLoss
-215660000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1090000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1984000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
128008000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10803000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
328000
us-gaap Interest Paid
InterestPaid
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
91000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
16760000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
4133000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
73643000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
299896000
ziop Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
270725000
ziop Issuance Of Warrants To Placement Agent In Public Offering
IssuanceOfWarrantsToPlacementAgentInPublicOffering
47276000
CY2011Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-7000
CY2011Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
78000
CY2011Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
724000
CY2011Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-227000
CY2011Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2011Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2011Q1 us-gaap Revenues
Revenues
67000
CY2011Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
186000
CY2011Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8167000
CY2011Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
17457000
CY2011Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
209000
CY2011Q1 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-11080000
CY2011Q1 us-gaap Share Based Compensation
ShareBasedCompensation
702000
CY2011Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1324000
CY2011Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
27993000
CY2011Q1 us-gaap Net Income Loss
NetIncomeLoss
-39008000
CY2011Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
5000000
CY2011Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24641000
CY2011Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
227000
CY2011Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
37000
CY2011Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-27926000
CY2011Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-11080000
CY2011Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
822000
CY2011Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
63645000
CY2011Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
510000
CY2011Q1 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-7000
CY2011Q1 us-gaap Interest Paid
InterestPaid
CY2011Q1 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
4000
CY2011Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
4933000
CY2011Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3352000
CY2011Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
72039000
CY2011Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2011Q1 ziop Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
71207000
CY2011Q1 ziop Weighted Average Number Basic Diluted Shares Outstanding
WeightedAverageNumberBasicDilutedSharesOutstanding
60412689 shares
CY2012Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2012Q1 dei Trading Symbol
TradingSymbol
ZIOP
CY2012Q1 dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
CY2012Q1 dei Amendment Flag
AmendmentFlag
false
CY2012Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2012Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
CY2012Q1 dei Document Type
DocumentType
10-Q
CY2012Q1 dei Document Period End Date
DocumentPeriodEndDate
2012-03-31
CY2012Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001107421
CY2012Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2012Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
23000
CY2012Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1212000
CY2012Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-154000
CY2012Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26000
CY2012Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2012Q1 us-gaap Revenues
Revenues
200000
CY2012Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3426000
CY2012Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
140000
CY2012Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9490000
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25860000
CY2012Q1 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
133000
CY2012Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
42000
CY2012Q1 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-5811000
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1212000
CY2012Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
713000
CY2012Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
18833000
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-24470000
CY2012Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-79000
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13985000
CY2012Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
49169000
CY2012Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
154000
CY2012Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
118000
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-18633000
CY2012Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-5811000
CY2012Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
257000
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
23295000
CY2012Q1 us-gaap Interest Paid
InterestPaid
CY2012Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-200000
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4848000
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49309000
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2012Q1 ziop Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
49169000
CY2012Q1 ziop Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
182000
CY2012Q1 ziop Weighted Average Number Basic Diluted Shares Outstanding
WeightedAverageNumberBasicDilutedSharesOutstanding
75620130 shares

Files In Submission

Name View Source Status
0001144204-12-025871-index-headers.html Edgar Link pending
0001144204-12-025871-index.html Edgar Link pending
0001144204-12-025871.txt Edgar Link pending
0001144204-12-025871-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v311108_10q.htm Edgar Link pending
v311108_ex10-1.htm Edgar Link pending
v311108_ex31-1.htm Edgar Link pending
v311108_ex31-2.htm Edgar Link pending
v311108_ex32-1.htm Edgar Link pending
ziop-20120331.xml Edgar Link completed
ziop-20120331.xsd Edgar Link pending
ziop-20120331_cal.xml Edgar Link unprocessable
ziop-20120331_def.xml Edgar Link unprocessable
ziop-20120331_lab.xml Edgar Link unprocessable
ziop-20120331_pre.xml Edgar Link unprocessable